Active substance
Clorazepate
- US FDA 67
- Health Canada 3
- US price lines 3
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRANXENE | 7.5MG | tablet · oral | AJENAT PHARMS | Prescription | 23 Jun 1972 |
| CLORAZEPATE DIPOTASSIUM | 15MG; 3.75MG; 7.5MG | tablet · oral | AUROBINDO PHARMA | Prescription | 17 Jul 1987 |
| CLORAZEPATE DIPOTASSIUM | 15MG; 7.5MG; 3.75MG | tablet · oral | TARO | Prescription | 27 Apr 2000 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG; 7.5MG; 15MG | tablet · oral | COREPHARMA | Prescription | 14 Jun 2022 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG; 7.5MG; 15MG | tablet · oral | NOVITIUM PHARMA | Prescription | 16 Jun 2022 |
| TRANXENE | 3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | AJENAT PHARMS | Discontinued | 23 Jun 1972 |
| TRANXENE SD | 22.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 11.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | AJENAT PHARMS | Discontinued | 23 Jun 1972 |
| TRANXENE | 3.75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | AJENAT PHARMS | Discontinued | 23 Jun 1972 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG | tablet · oral | ABLE | Discontinued | 26 Jun 1987 |
| CLORAZEPATE DIPOTASSIUM | 7.5MG | tablet · oral | ABLE | Discontinued | 26 Jun 1987 |
| CLORAZEPATE DIPOTASSIUM | 15MG | tablet · oral | ABLE | Discontinued | 26 Jun 1987 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG | capsule · oral | ABLE | Discontinued | 14 Jul 1987 |
| CLORAZEPATE DIPOTASSIUM | 7.5MG | capsule · oral | ABLE | Discontinued | 14 Jul 1987 |
| CLORAZEPATE DIPOTASSIUM | 15MG | capsule · oral | ABLE | Discontinued | 14 Jul 1987 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG | capsule · oral | NATCO PHARMA USA | Discontinued | 19 Oct 1987 |
| CLORAZEPATE DIPOTASSIUM | 7.5MG | capsule · oral | NATCO PHARMA USA | Discontinued | 19 Oct 1987 |
| CLORAZEPATE DIPOTASSIUM | 15MG | capsule · oral | NATCO PHARMA USA | Discontinued | 19 Oct 1987 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG | capsule · oral | DAVA PHARMS INC | Discontinued | 14 Dec 1987 |
| CLORAZEPATE DIPOTASSIUM | 7.5MG | capsule · oral | DAVA PHARMS INC | Discontinued | 14 Dec 1987 |
| CLORAZEPATE DIPOTASSIUM | 15MG | capsule · oral | DAVA PHARMS INC | Discontinued | 14 Dec 1987 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG | capsule · oral | GD SEARLE LLC | Discontinued | 18 Dec 1987 |
| CLORAZEPATE DIPOTASSIUM | 7.5MG | capsule · oral | GD SEARLE LLC | Discontinued | 18 Dec 1987 |
| CLORAZEPATE DIPOTASSIUM | 15MG | capsule · oral | GD SEARLE LLC | Discontinued | 18 Dec 1987 |
| CLORAZEPATE DIPOTASSIUM | 3.75MG | tablet · oral | WATSON LABS | Discontinued | 9 Feb 1988 |
| CLORAZEPATE DIPOTASSIUM | 7.5MG | tablet · oral | WATSON LABS | Discontinued | 9 Feb 1988 |
42 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CLORAZEPATE | 00860689 | 3.75 MG | CAPSULE · ORAL | AA PHARMA INC |
| CLORAZEPATE | 00860697 | 15 MG | CAPSULE · ORAL | AA PHARMA INC |
| CLORAZEPATE | 00860700 | 7.5 MG | CAPSULE · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CLORAZEPATE 15 MG TABLET | $0.80796 | per EA | 23 Sep 2026 |
| US NADAC | CLORAZEPATE 3.75 MG TABLET | $0.52409 | per EA | 23 Sep 2026 |
| US NADAC | CLORAZEPATE 7.5 MG TABLET | $0.83861 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 13 Jan 2023 TRANXENE — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Jan 2023 TRANXENE SD — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.